drugset / Trial / NCT05279417
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.
Timeline
- Start
- 2022-02-01
- Primary completion
- 2023-09-05
- Completion
- 2023-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zunsemetinib | Small molecule | 20 mg | Oral |
| Subject | Zunsemetinib | Small molecule | 50 mg | Oral |
| Background | Methotrexate | Small molecule | 15 mg | — |
| Background | Methotrexate | Small molecule | 25 mg | — |